Rose McNulty

In 179 patients with essential thrombocythemia, higher ropeginterferon alfa-2b exposure was linked to larger JAK2V617F allele burden drops at 6 months.

The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.

Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.

Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.

At ASN Kidney Week 2026, experts said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.

Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.

Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.

ASN Kidney Week 2026 experts discussed GLP-1 RAs alongside lifestyle care, global access, and bariatric surgery for obesity in chronic kidney disease.

Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.

Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.

Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.

An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.

Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.

Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.

FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.

A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

Fewer than half of phase 3 chronic spontaneous urticaria (CSU) trials reported baseline disease duration, a review found.

Expert guidance shows how to safely tailor aesthetic dermatology for allergic skin conditions like urticaria and eczema.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.